Please click here to view on demand.
Demy Colton
July 20, 2022 – Biotechnology Midyear Outlook
Global industries and economies continue on their wild ride, sparked from the pandemic, which thrusted biotechnology center stage during the development of vaccines and therapies. However, sentiment has cooled, driven by a convergence of complex factors, making identifying the next wave of emerging risks and opportunities an acute challenge. Armed with world class pharmaceutical industry, company, drug development, and financial data, Bloomberg Intelligence analysts join Demy-Colton to discuss the data-driven outlook for the biotech sector, for the balance of the year.
May 18, 2022 – U.S. Market Access Strategy at the Clinical Stage for All Companies Considering a Launch: A Three-Part Series
Sara Demy, CEO of Demy-Colton, hosts interactive virtual salons featuring industry leaders and distinguished guests exploring today’s most consequential and disruptive topics in healthcare.
U.S. MARKET ACCESS STRATEGY AT THE CLINICAL STAGE FOR ALL COMPANIES CONSIDERING A LAUNCH: A Three-Part Series
The complexity of the U.S. market access landscape means that proving safety and efficacy is no longer a guarantee of commercial success. This three-part series will provide you with the basics of government and commercial payer rules, walk through hypotheticals that bring those rules to life, and prepare you for the market’s evolving focus on value-delivery. At the end of the series, you will understand why your market access strategy can and should start before the initiation of your Phase IIIs, have identified early-stage steps to de-risk those variables with the potential to constrain market access later, and why you should be prepared for investors to ask you these same questions. This series will benefit any company new to the U.S. market, or looking to launch in the U.S.
The complexity of the U.S. market access landscape means that proving safety and efficacy is no longer a guarantee of commercial success. This three-part series will provide you with the basics of government and commercial payer rules, walk through hypotheticals that bring those rules to life, and prepare you for the market’s evolving focus on value-delivery. At the end of the series, you will understand why your market access strategy can and should start before the initiation of your Phase IIIs, have identified early-stage steps to de-risk those variables with the potential to constrain market access later, and why you should be prepared for investors to ask you these same questions. This series will benefit any company new to the U.S. market, or looking to launch in the U.S.
PART 3 OF 3
Future-Proofing: How to Prepare a Value-Based Market Access Strategy
Market access considerations continue to evolve in the highly dynamic U.S. market. With an increasing focus on value delivery, Part 3 will discuss the different ways to measure and demonstrate value, the interplay between FDA and CMS on such value propositions, and strategies for payer engagement.
March 17, 2022 – Getting to the Next Normal: A Roadmap for Living with COVID
Sara Demy, CEO of Demy-Colton, hosts interactive virtual salons featuring industry leaders and distinguished guests exploring today’s most consequential and disruptive topics in healthcare.
Getting to the Next Normal: A Roadmap for Living with COVID
To reach the next normal, we must implement a comprehensive and coordinated roadmap that addresses this pandemic and develops the capacity to confront future biosecurity threats. The shift to the next normal today should not induce complacency, inaction, or premature triumphalism
Insights from key thought leaders in life sciences and digital health
Industry leaders and distinguished guests gather online for interactive discussions to explore the most important topics in healthcare.
All Sessions are Complimentary!
Coming soon!
The Biotech CEO Summit Europe web site is coming soon.
You must be logged in to post a comment.